---
title: "Education and Alzheimer’s Genetic Risk Do Not Explain GLP-1 RA Associations With Dementia in Type"
id: "medrxiv-23-education-and-alzheimer-disease-genetic-risk-in-associations-of-glp-1-receptor"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-23-education-and-alzheimer-disease-genetic-risk-in-associations-of-glp-1-receptor"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.04.26362304v1?rss=1"
published_at: "2026-09-08T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Education and Alzheimer’s Genetic Risk Do Not Explain GLP-1 RA Associations With Dementia in Type
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-23-education-and-alzheimer-disease-genetic-risk-in-associations-of-glp-1-receptor
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.04.26362304v1?rss=1)
- **Published At:** 2026-09-08T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This observational cohort study used linked electronic health record, survey, and genetic data from 14,364 All of Us Research Program participants with **type 2 diabetes** to evaluate whether measured **educational attainment** and **Alzheimer disease genetic risk** influence associations between **GLP-1 receptor agonist** initiation and incident **dementia**. - Participants had a mean age of 60.2 years, 54.2% were female, and mean follow-up was 4.3 years. - Investigators compared GLP-1 receptor agonist initiators with initiators of non–sodium-glucose cotransporter 2 (non‑SGLT2) second-line therapies, and also used a separate SGLT2 inhibitor comparison. - Key analytic approach involved estimating hazard ratios for incident dementia before and after additional adjustment for measured educational attainment, APOE ε4, and non‑APOE genetic risk scores for Alzheimer disease. - The estimated hazard ratio (HR) for dementia comparing GLP-1 receptor agonist initiation with non‑SGLT2 second‑line therapy initiators was 0.85 (95% CI 0.64–1.12) before adjustment and 0.84 (95% CI 0.64–1.12) after adjustment for education and Alzheimer disease genetic susceptibility. - Adjustment for measured education and genetic susceptibility produced minimal change in the point estimate, suggesting these measured factors did not materially confound the observed association in this cohort. - The authors note these results do not exclude confounding by these factors in other populations or residual confounding from other socioeconomic, clinical, behavioral, or health‑care related variables. - Data are available to authorized researchers via the All of Us Researcher Workbench; the study is a preprint and has not undergone peer review.
## Clinical Analysis & Structured Key Points
Education and Alzheimer Disease Genetic Risk in Associations of GLP-1 Receptor Agonists With Dementia Among Adults With Type 2 Diabetes | medRxiv Skip to main content Education and Alzheimer Disease Genetic Risk in Associations of GLP-1 Receptor Agonists With Dementia Among Adults With Type 2 Diabetes Jingxuan Wang , Anna M. Pederson , Michael D. Flanders , Minhyuk Choi , Peter Buto , Kendra D. Sims , Ruijia Chen , Elyse Couch , Paola Gilsanz , Kaleen N. Hayes , Andrew R. Zullo , Andrew Stokes , Maria M. Glymour , Sarah F. Ackley doi: https://doi.org/10.64898/2026.09.04.26362304 Jingxuan Wang 1 Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115; Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02129; Department of Epidemiology, Boston University, Boston, MA 02118; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Anna M. Pederson 2 Department of Epidemiology, Boston University, Boston, MA 02118; Department of Epidemiology and Biostatistics, University of California, San Francisco, CA 94158; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Michael D. Flanders 3 Department of Epidemiology, Brown University, Providence, RI 02903; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Minhyuk Choi 4 Department of Epidemiology and Biostatistics, University of California, San Francisco, CA 94158; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Peter Buto 5 Department of Epidemiology, Boston University, Boston, MA 02118; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Kendra D. Sims 5 Department of Epidemiology, Boston University, Boston, MA 02118; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ruijia Chen 5 Department of Epidemiology, Boston University, Boston, MA 02118; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Elyse Couch 6 Department of Health Services, Policy, & Practice, Brown University, Providence, RI 02903; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Paola Gilsanz 7 Division of Research, Kaiser Permanente Northern California, Pleasanton, CA 94588 Find this author on Google Scholar Find this author on PubMed Search for this author on this site Kaleen N. Hayes 6 Department of Health Services, Policy, & Practice, Brown University, Providence, RI 02903; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Andrew R. Zullo 3 Department of Epidemiology, Brown University, Providence, RI 02903; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Andrew Stokes 7 Division of Research, Kaiser Permanente Northern California, Pleasanton, CA 94588 Find this author on Google Scholar Find this author on PubMed Search for this author on this site Maria M. Glymour 5 Department of Epidemiology, Boston University, Boston, MA 02118; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Sarah F. Ackley 3 Department of Epidemiology, Brown University, Providence, RI 02903; Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: sarah_ackley{at}brown.edu Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Objective: To evaluate whether educational attainment and Alzheimer disease genetic risk were associated with GLP-1 receptor agonist initiation and dementia incidence and whether adjustment for these measured factors materially changed the estimated association between GLP-1 receptor agonist initiation and incident dementia among adults with type 2 diabetes. Research Design and Methods: We conducted an observational cohort study using linked electronic health record, survey, and genetic data from 14,364 All of Us Research Program participants with type 2 diabetes. We estimated associations of educational attainment and Alzheimer disease genetic risk with treatment initiation and incident dementia and compared GLP-1 receptor agonist initiators with initiators of non-sodium-glucose cotransporter 2 inhibitor second-line therapies, with a separate sodium-glucose cotransporter 2 inhibitor comparison. Models were estimated before and after additional adjustment for educational attainment, APOE ε4, and non-APOE genetic risk. Results: Among 14,364 participants (mean age, 60.2 years; 54.2% female), the mean follow-up duration was 4.3 years. The estimated hazard ratio for dementia comparing GLP-1 receptor agonist initiation with non-SGLT2 inhibitor second-line therapy was 0.85 (95% CI 0.64-1.12) before adjustment for education or Alzheimer disease genetic risk and 0.84 (95% CI 0.64-1.12) after adjustment for educational attainment, APOE ε4, and non-APOE genetic risk. Conclusions: Among adults with type 2 diabetes, adjustment for measured educational attainment and Alzheimer disease genetic susceptibility produced little change in the estimated association between GLP-1 receptor agonist initiation and incident dementia. These findings do not exclude confounding by these factors in other populations or residual confounding from socioeconomic, clinical, behavioral, and health-care-related factors. Competing Interest Statement Funding: JW is supported by NIH NIA K00AG083306. SFA and MDF are supported by NIH NIA R00AG073454. KDS is supported by NIH NIA R00AG083121 and L60AG089791. MMG, JW, KDS, RC, PB, AMP, and MC are supported by NIH NIA P01AG082653. KNH is supported by NIH NIA RF1AG089541 and RF1AG087210. PG is supported by NIH NIA R01AG067199. R.C. was supported by NIH NIA K99AG088369 and AARFD-24-1308786. ARZ is supported by NIA awards R01AG077620, R01AG088522, RF1AG089541, and U24AG087939. Disclosures: Brown University has received grant funding on behalf of SFA from Sanofi for unrelated projects. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study used data from the All of Us Researcher Workbench. The data available to researchers have had direct identifiers removed and have been further modified to minimize re-identification risk. Research conducted solely within the All of Us Researcher Workbench is not considered human subjects research under the Common Rule. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability Data are available to authorized researchers through the All of Us Researcher Workbench, subject to program access requirements. Funder Information Declared Funding: JW is supported by NIH NIA K00AG083306. SFA and MDF are supported by NIH NIA R00AG073454. KDS is supported by NIH NIA R00AG083121 and L60AG089791. MMG, JW, KDS, RC, PB, AMP, and MC are supported by NIH NIA P01AG082653. KNH is supported by NIH NIA RF1AG089541 and RF1AG087210. PG is supported by NIH NIA R01AG067199. R.C. was supported by NIH NIA K99AG088369 and AARFD-24-1308786. ARZ is supported by NIA awards R01AG077620, R01AG088522, RF1AG089541, and U24AG087939. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Back to top Previous Next Posted September 08, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Education and Alzheimer Disease Genetic Risk in Associations of GLP-1 Receptor Agonists With Dementia Among Adults With Type 2 Diabetes Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Education and Alzheimer Disease Genetic Risk in Associations of GLP-1 Receptor Agonists With Dementia Among Adults With Type 2 Diabetes Jingxuan Wang , Anna M. Pederson , Michael D. Flanders , Minhyuk Choi , Peter Buto , Kendra D. Sims , Ruijia Chen , Elyse Couch , Paola Gilsanz , Kaleen N. Hayes , Andrew R. Zullo , Andrew Stokes , Maria M. Glymour , Sarah F. Ackley medRxiv 2026.09.04.26362304; doi: https://doi.org/10.64898/2026.09.04.26362304 Share This Article: Copy Citation Tools Education and Alzheimer Disease Genetic Risk in Associations of GLP-1 Receptor Agonists With Dementia Among Adults With Type 2 Diabetes Jingxuan Wang , Anna M. Pederson , Michael D. Flanders , Minhyuk Choi , Peter Buto , Kendra D. Sims , Ruijia Chen , Elyse Couch , Paola Gilsanz , Kaleen N. Hayes , Andrew R. Zullo , Andrew Stokes , Maria M. Glymour , Sarah F. Ackley medRxiv 2026.09.04.26362304; doi: https://doi.org/10.64898/2026.09.04.26362304 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (616) Allergy and Immunology (897) Anesthesia (329) Cardiovascular Medicine (4786) Dentistry and Oral Medicine (477) Dermatology (412) Emergency Medicine (647) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1618) Epidemiology (15877) Forensic Medicine (32) Gastroenterology (1199) Genetic and Genomic Medicine (7009) Geriatric Medicine (729) Health Economics (1060) Health Informatics (5015) Health Policy (1429) Health Systems and Quality Improvement (1748) Hematology (583) HIV/AIDS (1340) Infectious Diseases (except HIV/AIDS) (16265) Intensive Care and Critical Care Medicine (1165) Medical Education (666) Medical Ethics (151) Nephrology (721) Neurology (7221) Nursing (366) Nutrition (1074) Obstetrics and Gynecology (1234) Occupational and Environmental Health (1002) Oncology (3585) Ophthalmology (1045) Orthopedics (396) Otolaryngology (449) Pain Medicine (466) Palliative Medicine (139) Pathology (705) Pediatrics (1784) Pharmacology and Therapeutics (733) Primary Care Research (760) Psychiatry and Clinical Psychology (5854) Public and Global Health (9724) Radiology and Imaging (2400) Rehabilitation Medicine and Physical Therapy (1440) Respiratory Medicine (1245) Rheumatology (636) Sexual and Reproductive Health (769) Sports Medicine (577) Surgery (774) Toxicology (107) Transplantation (303) Urology (288)
## Related Clinical Research

- [AD-Smart trial to repurpose diabetes and ADHD drugs for Alzheimer’s patients](https://medichelpline.com/clinical-feed/bmj-0-ad-smart-alzheimer-x2019-s-trial-will-test-diabetes-and-adhd-drugs-on-patients.md)
- [Ultra-processed foods linked to MRI signs of vascular brain injury in middle-aged adults](https://medichelpline.com/clinical-feed/medical-news-today-0-ultra-processed-foods-may-be-harming-brain-health-in-otherwise-healthy-adults.md)
- [Global dementia incidence projected to reach 24.7 million new cases annually by 2050](https://medichelpline.com/clinical-feed/medical-news-today-0-dementia-cases-to-double-by-2050-why-women-some-countries-may-be-at-higher-risk.md)
- [Sex differences in genetic links between modifiable risk factors and Alzheimer’s disease](https://medichelpline.com/clinical-feed/medrxiv-15-sex-differences-in-genetic-liability-to-modifiable-alzheimer-s-disease-risk.md)
- [GLP‑1 Receptor Agonists and SGLT2 Inhibitors Linked to Lower Alzheimer Risk in Type 2 Diabetes](https://medichelpline.com/clinical-feed/medrxiv-20-glp-1-receptor-agonists-vs-sglt2-inhibitors-for-alzheimer-disease-risk-in-type.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.